165 related articles for article (PubMed ID: 36974638)
1. Is the combination of linagliptin and allopurinol better prophylaxis against post-contrast acute kidney injury? A multicenter prospective randomized controlled study.
Fayed A; Hammad AA; Abdulazim DO; Hammad H; Amin M; Elhadidy S; Salem MM; ElAzim IMA; Zsom L; Csongradi E; Soliman KM; Sharaf El Din UA
Ren Fail; 2023 Dec; 45(1):2194434. PubMed ID: 36974638
[TBL] [Abstract][Full Text] [Related]
2. Prevention of contrast-induced nephropathy with single bolus erythropoietin in patients with diabetic kidney disease: A randomized controlled trial.
Shema-Didi L; Kristal B; Eizenberg S; Marzuq N; Sussan M; Feldman-Idov Y; Ofir P; Atar S
Nephrology (Carlton); 2016 Apr; 21(4):295-300. PubMed ID: 26370061
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis on allopurinol preventive intervention on contrast-induced acute kidney injury with random controlled trials: PRISMA.
Ma G; Wang G; Xiao D; Teng W; Hui X; Ma G
Medicine (Baltimore); 2019 Jun; 98(25):e15962. PubMed ID: 31232927
[TBL] [Abstract][Full Text] [Related]
4. Variation in contrast-associated acute kidney injury prophylaxis for percutaneous coronary intervention: insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) program.
Keach JW; Stanislawski MA; Barón AE; Plomondon ME; Langner P; Amin A; Gilmartin HM; Waldo S; Maddox TM
BMC Nephrol; 2020 Apr; 21(1):150. PubMed ID: 32345254
[TBL] [Abstract][Full Text] [Related]
5. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial.
Brueck M; Cengiz H; Hoeltgen R; Wieczorek M; Boedeker RH; Scheibelhut C; Boening A
J Invasive Cardiol; 2013 Jun; 25(6):276-83. PubMed ID: 23735352
[TBL] [Abstract][Full Text] [Related]
7. Prevention of postcontrast acute kidney injury after percutaneous transluminal angioplasty by inducing RenalGuard controlled furosemide forced diuresis with matched hydration: study protocol for a randomised controlled trial.
Bolt LJJ; Sigterman TA; Krasznai AG; Sikkink CJM; Schurink GH; Bouwman LH
BMJ Open; 2018 Oct; 8(9):e021842. PubMed ID: 30287607
[TBL] [Abstract][Full Text] [Related]
8. Effects of allopurinol pretreatment on the risk of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials
.
Xin W; Lin Z; Zhang T; Jia S
Clin Nephrol; 2020 Jan; 93(1):24-33. PubMed ID: 31661061
[TBL] [Abstract][Full Text] [Related]
9. Do intravenous N-acetylcysteine and sodium bicarbonate prevent high osmolal contrast-induced acute kidney injury? A randomized controlled trial.
Inda-Filho AJ; Caixeta A; Manggini M; Schor N
PLoS One; 2014; 9(9):e107602. PubMed ID: 25254489
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of vitamin E and N-acetylcysteine in the prevention of contrast induced kidney injury in patients with chronic kidney disease: a double blind, randomized controlled trial.
Kitzler TM; Jaberi A; Sendlhofer G; Rehak P; Binder C; Petnehazy E; Stacher R; Kotanko P
Wien Klin Wochenschr; 2012 May; 124(9-10):312-9. PubMed ID: 22527829
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of allopurinol pretreatment for prevention of contrast-induced nephropathy: a randomized controlled trial.
Erol T; Tekin A; Katırcıbaşı MT; Sezgin N; Bilgi M; Tekin G; Zümrütdal A; Sezgin AT; Müderrisoğlu H
Int J Cardiol; 2013 Aug; 167(4):1396-9. PubMed ID: 22572633
[TBL] [Abstract][Full Text] [Related]
12. New strategy of α- and γ-tocopherol to prevent contrast-induced acute kidney injury in chronic kidney disease patients undergoing elective coronary procedures.
Tasanarong A; Vohakiat A; Hutayanon P; Piyayotai D
Nephrol Dial Transplant; 2013 Feb; 28(2):337-44. PubMed ID: 23314316
[TBL] [Abstract][Full Text] [Related]
13. Sodium bicarbonate plus N-acetylcysteine prophylaxis: a meta-analysis.
Brown JR; Block CA; Malenka DJ; O'Connor GT; Schoolwerth AC; Thompson CA
JACC Cardiovasc Interv; 2009 Nov; 2(11):1116-24. PubMed ID: 19926054
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
Han SY; Yoon SA; Han BG; Kim SG; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang Y; Kim B; Shin S; Cha DR
Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008
[TBL] [Abstract][Full Text] [Related]
15. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease.
Han Y; Zhu G; Han L; Hou F; Huang W; Liu H; Gan J; Jiang T; Li X; Wang W; Ding S; Jia S; Shen W; Wang D; Sun L; Qiu J; Wang X; Li Y; Deng J; Li J; Xu K; Xu B; Mehran R; Huo Y
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):62-70. PubMed ID: 24076297
[TBL] [Abstract][Full Text] [Related]
16. DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes.
Fadini GP; Bonora BM; Albiero M; Zaninotto M; Plebani M; Avogaro A
Cardiovasc Diabetol; 2017 Feb; 16(1):22. PubMed ID: 28183314
[TBL] [Abstract][Full Text] [Related]
17. [Prevention of "contrast-induced" acute kidney injury - practical considerations].
Weidenbusch M; Wörnle M; Kazmierczak P; Ricke J; Fischereder M
Dtsch Med Wochenschr; 2019 Aug; 144(15):1009-1013. PubMed ID: 31350739
[TBL] [Abstract][Full Text] [Related]
18. The effect of linagliptin on renal progression in type-2 diabetes mellitus patients with chronic kidney disease: A prospective randomized controlled study.
Yagoglu AI; Dizdar OS; Erdem S; Akcakaya B; Gunal AI
Nefrologia (Engl Ed); 2020; 40(6):664-671. PubMed ID: 32736891
[TBL] [Abstract][Full Text] [Related]
19. Oral hydration compared to intravenous hydration in the prevention of post-contrast acute kidney injury in patients with chronic kidney disease stage IIIb: A phase III non-inferiority study (NICIR study).
Sebastià C; Páez-Carpio A; Guillen E; Paño B; Garcia-Cinca D; Poch E; Oleaga L; Nicolau C
Eur J Radiol; 2021 Mar; 136():109509. PubMed ID: 33516141
[TBL] [Abstract][Full Text] [Related]
20. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.
Perkovic V; Toto R; Cooper ME; Mann JFE; Rosenstock J; McGuire DK; Kahn SE; Marx N; Alexander JH; Zinman B; Pfarr E; Schnaidt S; Meinicke T; von Eynatten M; George JT; Johansen OE; Wanner C;
Diabetes Care; 2020 Aug; 43(8):1803-1812. PubMed ID: 32444457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
